Laurak (Levetiracetam)

• Levetiracetam is an anticonvulsant used to manage seizure disorders.
• Partial seizures: Decreases the number of focal onset seizures, with or without secondary generalization, improving seizure control in adults and children with epilepsy.
• Generalized tonic‑clonic seizures: Lowers the incidence of bilateral convulsive seizures, helping to achieve better overall seizure management in patients with generalized epilepsy.
• Myoclonic seizures: Reduces rapid, brief muscle jerks, contributing to improved daily functioning for individuals experiencing myoclonic epilepsy.
• Adjunct therapy in refractory epilepsy: Used alongside other antiepileptic drugs when seizures are not adequately controlled by monotherapy.

• Levetiracetam binds to the synaptic vesicle protein SV2A, a regulator of neurotransmitter release. This interaction modulates calcium‑dependent exocytosis, decreasing synaptic transmission of excitatory glutamate and stabilizing neuronal firing. By reducing neuronal hyper‑excitability, the drug helps prevent the initiation and spread of epileptic discharges. The exact downstream pathways remain under investigation, but the overall effect is a net reduction in the likelihood of seizure generation without significant interaction with G‑protein coupled receptors or ion channels.

Levetiracetam may cause a range of adverse reactions, varying from mild, transient symptoms to serious, potentially life‑threatening events, and patients should be monitored for any changes.

Common Side Effects

• Drowsiness: Feeling unusually sleepy or fatigued.
• Dizziness: Light‑headed sensation, especially when standing quickly.
• Headache: Mild to moderate head pain.
• Irritability or mood changes: Increased agitation or emotional lability.
• Nausea: Mild stomach upset, sometimes accompanied by loss of appetite.
• Insomnia: Difficulty falling or staying asleep, leading to reduced daytime alertness.

Serious or Rare Side Effects

• Severe allergic reaction: Rash, swelling, or difficulty breathing requiring immediate medical attention.
• Psychiatric symptoms: New or worsening depression, suicidal thoughts, or severe anxiety.
• Blood disorders: Unexplained bruising, bleeding, or low blood cell counts.

• When prescribing levetiracetam, clinicians should consider several precautionary measures to ensure safe use.
• Renal impairment: Adjust dose in patients with reduced kidney function, as it is cleared unchanged.
• Hepatic disease: Use caution; severe liver dysfunction may affect drug handling.
• Psychiatric history: Monitor for mood changes, depression, or suicidal ideation, especially in patients with prior psychiatric disorders.
• Concomitant CNS depressants: Observe for added sedation when combined with other CNS depressants.
• Pregnancy and lactation: Lack of definitive data; weigh potential benefits against unknown risks and consider alternative therapies.
• Store at ambient temperature: keep below 25°C, in original container, protected from moisture and light.

Levetiracetam may interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• Carbamazepine: Induces hepatic enzymes that can lower levetiracetam plasma levels, reducing seizure control.
• Phenobarbital: Enzyme induction may decrease levetiracetam concentrations, potentially compromising efficacy.
• Valproic acid: May increase levetiracetam levels, raising risk of adverse effects.

Moderate Interactions (Monitor Closely)

• Antidepressants (e.g., SSRIs): May increase risk of mood changes; monitor psychiatric status.
• Alcohol: Combined CNS depressant effect can enhance drowsiness and dizziness.
• Other antiepileptic drugs: May require dose adjustments; monitor seizure frequency.
• Cimetidine: Can modestly increase levetiracetam concentrations; observe for side effects.
• Oral contraceptives: May have reduced efficacy; advise alternative contraception methods.